Published in J Matern Fetal Neonatal Med on January 01, 2008
Clinical characterization and outcomes of preeclampsia with normal angiogenic profile. Hypertens Pregnancy (2013) 2.22
The course of angiogenic factors in early- vs. late-onset preeclampsia and HELLP syndrome. J Perinat Med (2013) 2.06
Defining normal and abnormal fetal growth: promises and challenges. Am J Obstet Gynecol (2010) 2.05
The "Great Obstetrical Syndromes" are associated with disorders of deep placentation. Am J Obstet Gynecol (2010) 1.99
Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation (2012) 1.88
A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia. J Matern Fetal Neonatal Med (2009) 1.84
Placental vascular pathology findings and pathways to preterm delivery. Am J Epidemiol (2009) 1.73
Recent advances in the understanding of the pathophysiology of preeclampsia. Hypertension (2013) 1.71
The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age. J Matern Fetal Neonatal Med (2008) 1.60
Angiogenic factors and preeclampsia. Semin Nephrol (2011) 1.58
Fetal growth restriction and chronic lung disease among infants born before the 28th week of gestation. Pediatrics (2009) 1.49
Epidemiology and Mechanisms of De Novo and Persistent Hypertension in the Postpartum Period. Circulation (2015) 1.46
Potential markers of preeclampsia--a review. Reprod Biol Endocrinol (2009) 1.44
Soluble fms-Like tyrosine kinase 1 (sFlt1), endoglin and placental growth factor (PlGF) in preeclampsia among high risk pregnancies. PLoS One (2010) 1.25
A brief overview of preeclampsia. J Clin Med Res (2013) 1.23
Maternal plasma concentrations of angiogenic/anti-angiogenic factors are of prognostic value in patients presenting to the obstetrical triage area with the suspicion of preeclampsia. J Matern Fetal Neonatal Med (2011) 1.13
DBA-lectin reactivity defines mouse uterine natural killer cell subsets with biased gene expression. Biol Reprod (2012) 1.11
Angiogenic factors in diagnosis, management, and research in preeclampsia. Hypertension (2013) 1.11
Is inflammation the cause of pre-eclampsia? Biochem Soc Trans (2011) 1.09
A subset of patients destined to develop spontaneous preterm labor has an abnormal angiogenic/anti-angiogenic profile in maternal plasma: evidence in support of pathophysiologic heterogeneity of preterm labor derived from a longitudinal study. J Matern Fetal Neonatal Med (2009) 1.09
Late-onset preeclampsia is associated with an imbalance of angiogenic and anti-angiogenic factors in patients with and without placental lesions consistent with maternal underperfusion. J Matern Fetal Neonatal Med (2011) 1.07
Maternal plasma concentrations of angiogenic/antiangiogenic factors in the third trimester of pregnancy to identify the patient at risk for stillbirth at or near term and severe late preeclampsia. Am J Obstet Gynecol (2013) 1.05
Epistasis between COMT and MTHFR in maternal-fetal dyads increases risk for preeclampsia. PLoS One (2011) 1.04
Placental lesions associated with maternal underperfusion are more frequent in early-onset than in late-onset preeclampsia. J Perinat Med (2011) 1.01
The interrelationship of complement-activation fragments and angiogenesis-related factors in early pregnancy and their association with pre-eclampsia. BJOG (2010) 1.01
Pre-eclampsia: the pivotal role of the placenta in its pathophysiology and markers for early detection. Ther Adv Cardiovasc Dis (2008) 0.99
New developments in the pathogenesis of preeclampsia. Adv Chronic Kidney Dis (2013) 0.97
Effects of hypoxia-inducible factor-1alpha overexpression in pregnant mice: possible implications for preeclampsia and intrauterine growth restriction. Am J Pathol (2010) 0.96
Low placental growth factor across pregnancy identifies a subset of women with preterm preeclampsia: type 1 versus type 2 preeclampsia? Hypertension (2012) 0.96
Circulating and placental endoglin concentrations in pregnancies complicated by intrauterine growth restriction and preeclampsia. Placenta (2008) 0.96
An imbalance between angiogenic and anti-angiogenic factors precedes fetal death in a subset of patients: results of a longitudinal study. J Matern Fetal Neonatal Med (2010) 0.95
Microbial invasion of the amniotic cavity in pregnancies with small-for-gestational-age fetuses. J Perinat Med (2010) 0.95
Circulating soluble endoglin and placental abruption. Prenat Diagn (2008) 0.93
Identification of the primary outcomes that result from deficient spiral arterial modification in pregnant mice. Pregnancy Hypertens (2011) 0.92
Preeclampsia and the Anti-Angiogenic State. Pregnancy Hypertens (2011) 0.92
Gestation dependant changes in angiogenic factors and their associations with fetal growth measures in normotensive pregnancy. PLoS One (2013) 0.92
Twin-to-twin transfusion syndrome: an antiangiogenic state? Am J Obstet Gynecol (2008) 0.92
Microbial invasion of the amniotic cavity in preeclampsia as assessed by cultivation and sequence-based methods. J Perinat Med (2010) 0.92
Exposure to experimental preeclampsia in mice enhances the vascular response to future injury. Hypertension (2015) 0.92
Maternal serum adiponectin multimers in preeclampsia. J Perinat Med (2009) 0.92
Beyond the threshold: an etiological bridge between hypoxia and immunity in preeclampsia. J Reprod Immunol (2010) 0.91
Severe preeclampsia is characterized by increased placental expression of galectin-1. J Matern Fetal Neonatal Med (2008) 0.91
Aspirin for prevention of preeclampsia in lupus pregnancy. Autoimmune Dis (2014) 0.90
Midpregnancy levels of angiogenic markers in relation to maternal characteristics. Am J Obstet Gynecol (2010) 0.89
Effect of antihypertensive therapy with alpha methyldopa on levels of angiogenic factors in pregnancies with hypertensive disorders. PLoS One (2008) 0.89
Preeclampsia and pregnancies with small-for-gestational age neonates have different profiles of complement split products. J Matern Fetal Neonatal Med (2010) 0.88
Implementation of the sFlt-1/PlGF ratio for prediction and diagnosis of pre-eclampsia in singleton pregnancy: implications for clinical practice. Ultrasound Obstet Gynecol (2015) 0.88
Circulating angiogenic and antiangiogenic factors in women with eclampsia. Am J Obstet Gynecol (2010) 0.88
Pre-eclampsia: its pathogenesis and pathophysiolgy. Cardiovasc J Afr (2016) 0.88
Vasoactive agents for the prediction of early- and late-onset preeclampsia in a high-risk cohort. BMC Pregnancy Childbirth (2013) 0.88
Circulating angiogenic factors in gestational proteinuria without hypertension. Am J Obstet Gynecol (2009) 0.88
Evidence of an imbalance of angiogenic/antiangiogenic factors in massive perivillous fibrin deposition (maternal floor infarction): a placental lesion associated with recurrent miscarriage and fetal death. Am J Obstet Gynecol (2013) 0.87
Plasma concentrations of angiogenic/anti-angiogenic factors have prognostic value in women presenting with suspected preeclampsia to the obstetrical triage area: a prospective study. J Matern Fetal Neonatal Med (2013) 0.87
Retinol binding protein 4--a novel association with early-onset preeclampsia. J Perinat Med (2010) 0.87
Plasma soluble endoglin concentration in pre-eclampsia is associated with an increased impedance to flow in the maternal and fetal circulations. Ultrasound Obstet Gynecol (2010) 0.86
Pravastatin to prevent recurrent fetal death in massive perivillous fibrin deposition of the placenta (MPFD). J Matern Fetal Neonatal Med (2015) 0.85
The maternal HLA-G 1597ΔC null mutation is associated with increased risk of pre-eclampsia and reduced HLA-G expression during pregnancy in African-American women. Mol Hum Reprod (2012) 0.85
A decrease in maternal plasma concentrations of sVEGFR-2 precedes the clinical diagnosis of preeclampsia. Am J Obstet Gynecol (2010) 0.85
Placental growth factor for the prediction of adverse outcomes in patients with suspected preeclampsia or intrauterine growth restriction. PLoS One (2012) 0.85
The role of angiogenic and antiangiogenic factors in the second trimester in the prediction of preeclampsia in pregnant women with type 1 diabetes. Diabetes Care (2013) 0.85
Unexplained fetal death is associated with increased concentrations of anti-angiogenic factors in amniotic fluid. J Matern Fetal Neonatal Med (2010) 0.85
Sera from preeclampsia patients elicit symptoms of human disease in mice and provide a basis for an in vitro predictive assay. Am J Pathol (2010) 0.85
Biomarkers for the management of pre-eclampsia in pregnant women. Indian J Med Res (2013) 0.84
New-onset maternal gestational hypertension and risk of retinopathy of prematurity. Invest Ophthalmol Vis Sci (2010) 0.84
Circulating soluble endoglin levels in pregnant women in Cameroon and Malawi--associations with placental malaria and fetal growth restriction. PLoS One (2011) 0.84
Evolutionary origins of the placental expression of chromosome 19 cluster galectins and their complex dysregulation in preeclampsia. Placenta (2014) 0.84
An Elevated Maternal Plasma Soluble fms-Like Tyrosine Kinase-1 to Placental Growth Factor Ratio at Midtrimester Is a Useful Predictor for Preeclampsia. Obstet Gynecol Int (2013) 0.83
Placental protein 13 (PP13/galectin-13) undergoes lipid raft-associated subcellular redistribution in the syncytiotrophoblast in preterm preeclampsia and HELLP syndrome. Am J Obstet Gynecol (2011) 0.83
Leukocytes of pregnant women with small-for-gestational age neonates have a different phenotypic and metabolic activity from those of women with preeclampsia. J Matern Fetal Neonatal Med (2010) 0.83
Maternal circulating angiogenic factors in twin and singleton pregnancies. Am J Obstet Gynecol (2014) 0.83
Dysregulation of maternal serum adiponectin in preterm labor. J Matern Fetal Neonatal Med (2009) 0.83
Serum and plasma determination of angiogenic and anti-angiogenic factors yield different results: the need for standardization in clinical practice. J Matern Fetal Neonatal Med (2010) 0.83
Levels of soluble fms-like tyrosine kinase one in first trimester and outcomes of pregnancy: a systematic review. Reprod Biol Endocrinol (2011) 0.83
Uterine Regulatory T cells, IL-10 and hypertension. Am J Reprod Immunol (2011) 0.82
Evidence in support of a role for anti-angiogenic factors in preterm prelabor rupture of membranes. J Matern Fetal Neonatal Med (2010) 0.82
Maternal serum adiponectin multimers in patients with a small-for-gestational-age newborn. J Perinat Med (2009) 0.82
Evaluation of current and new biomarkers in severe preeclampsia: a microarray approach reveals the VSIG4 gene as a potential blood biomarker. PLoS One (2013) 0.81
Baseline placental growth factor levels for the prediction of benefit from early aspirin prophylaxis for preeclampsia prevention. Pregnancy Hypertens (2015) 0.81
Polymorphisms in maternal and fetal genes encoding for proteins involved in extracellular matrix metabolism alter the risk for small-for-gestational-age. J Matern Fetal Neonatal Med (2010) 0.81
Associations of pregnancy characteristics with maternal and cord steroid hormones, angiogenic factors, and insulin-like growth factor axis. Cancer Causes Control (2011) 0.81
Acute pyelonephritis during pregnancy changes the balance of angiogenic and anti-angiogenic factors in maternal plasma. J Matern Fetal Neonatal Med (2010) 0.81
Do anti-angiogenic or angiogenic factors contribute to the protection of birth weight at high altitude afforded by Andean ancestry? Reprod Sci (2010) 0.81
Maternal serum endoglin as an early marker of pre-eclampsia in high-risk patients. Int J Womens Health (2012) 0.80
Low VEGF expression in conceptus material and maternal serum AFP and β-hCG levels as indicators of defective angiogenesis in first-trimester miscarriages. J Turk Ger Gynecol Assoc (2012) 0.80
In vivo experiments reveal the good, the bad and the ugly faces of sFlt-1 in pregnancy. PLoS One (2014) 0.80
Fetal death: a condition with a dissociation in the concentrations of soluble vascular endothelial growth factor receptor-2 between the maternal and fetal compartments. J Matern Fetal Neonatal Med (2010) 0.80
Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study. Am J Obstet Gynecol (2015) 0.80
Current best practice in the management of hypertensive disorders in pregnancy. Integr Blood Press Control (2016) 0.79
The imbalance in expression of angiogenic and anti-angiogenic factors as candidate predictive biomarker in preeclampsia. Iran J Reprod Med (2015) 0.79
Decreased seizure threshold in an eclampsia-like model induced in pregnant rats with lipopolysaccharide and pentylenetetrazol treatments. PLoS One (2014) 0.79
Maternal angiogenic profile in pregnancies that remain normotensive. Eur J Obstet Gynecol Reprod Biol (2011) 0.79
Could alterations in maternal plasma visfatin concentration participate in the phenotype definition of preeclampsia and SGA? J Matern Fetal Neonatal Med (2010) 0.79
Placental Growth Factor Administration Abolishes Placental Ischemia-Induced Hypertension. Hypertension (2016) 0.79
Maternal plasma soluble TRAIL is decreased in preeclampsia. J Matern Fetal Neonatal Med (2013) 0.79
Angiogenic factors in preeclampsia: potential for diagnosis and treatment. Curr Opin Nephrol Hypertens (2013) 0.79
Renal evaluation in women with preeclampsia. Nephron Extra (2012) 0.79
Increased protein-coding mutations in the mitochondrial genome of African American women with preeclampsia. Reprod Sci (2012) 0.79
Full-length human placental sFlt-1-e15a isoform induces distinct maternal phenotypes of preeclampsia in mice. PLoS One (2015) 0.78
The biology of VEGF and its receptors. Nat Med (2003) 32.13
Vascular-specific growth factors and blood vessel formation. Nature (2000) 14.42
Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med (2004) 14.00
Mechanisms of angiogenesis and arteriogenesis. Nat Med (2000) 13.88
Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest (2003) 13.72
Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev (2004) 11.69
Latest advances in understanding preeclampsia. Science (2005) 8.11
Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med (2006) 7.06
Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med (2006) 6.21
Preeclampsia: an endothelial cell disorder. Am J Obstet Gynecol (1989) 5.73
Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med (2002) 5.50
Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors. EMBO J (2002) 5.44
Preeclampsia: an excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol (1999) 4.74
Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development. Genes Dev (1999) 3.35
Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med (2003) 3.17
Recent Insights into the pathogenesis of pre-eclampsia. Placenta (2002) 2.91
Cytotrophoblasts up-regulate soluble fms-like tyrosine kinase-1 expression under reduced oxygen: an implication for the placental vascular development and the pathophysiology of preeclampsia. Endocrinology (2004) 2.83
Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-beta superfamily. J Biol Chem (1999) 2.77
Urinary placental growth factor and risk of preeclampsia. JAMA (2005) 2.76
VEGF receptor signal transduction. Sci STKE (2001) 2.75
Soluble vascular endothelial growth factor receptor-1 (sFlt-1) is increased throughout gestation in patients who have preeclampsia develop. Am J Obstet Gynecol (2004) 2.72
Etiology and pathogenesis of preeclampsia: current concepts. Am J Obstet Gynecol (1998) 2.72
Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders. J Thromb Haemost (2003) 2.49
Shared and disparate components of the pathophysiologies of fetal growth restriction and preeclampsia. Am J Obstet Gynecol (2006) 2.15
New doppler technique for assessing uteroplacental blood flow. Lancet (1983) 2.15
A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation. Biol Reprod (1998) 2.12
First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metab (2004) 2.11
Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences. J Clin Endocrinol Metab (2003) 2.07
Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia. J Matern Fetal Neonatal Med (2005) 1.99
[A national birth weight distribution curve according to gestational age in Chile from 1993 to 2000]. Rev Med Chil (2004) 1.94
Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. J Clin Endocrinol Metab (2003) 1.88
Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award. Am J Obstet Gynecol (2004) 1.81
Preeclampsia is associated with reduced serum levels of placenta growth factor. Am J Obstet Gynecol (1998) 1.79
Cytomegalovirus-induced mirror syndrome associated with elevated levels of circulating antiangiogenic factors. Obstet Gynecol (2007) 1.67
Longitudinal serum concentrations of placental growth factor: evidence for abnormal placental angiogenesis in pathologic pregnancies. Am J Obstet Gynecol (2003) 1.67
Soluble fms-like tyrosine kinase 1 is increased in preeclampsia but not in normotensive pregnancies with small-for-gestational-age neonates: relationship to circulating placental growth factor. J Clin Endocrinol Metab (2005) 1.61
Identification of a human endothelial cell antigen with monoclonal antibody 44G4 produced against a pre-B leukemic cell line. J Immunol (1988) 1.59
A longitudinal study of biochemical variables in women at risk of preeclampsia. Am J Obstet Gynecol (2002) 1.57
Multicenter screening for pre-eclampsia and fetal growth restriction by transvaginal uterine artery Doppler at 23 weeks of gestation. Ultrasound Obstet Gynecol (2001) 1.56
Endoglin: An accessory component of the TGF-beta-binding receptor-complex with diagnostic, prognostic, and bioimmunotherapeutic potential in human malignancies. J Cell Physiol (2001) 1.54
Endoglin modulates cellular responses to TGF-beta 1. J Cell Biol (1996) 1.50
Circulating concentrations of sFlt1 (soluble fms-like tyrosine kinase 1) in fetal and maternal serum during pre-eclampsia. Eur J Obstet Gynecol Reprod Biol (2005) 1.48
Role of endoglin in cellular responses to transforming growth factor-beta. A comparative study with betaglycan. J Biol Chem (1998) 1.44
Low maternal serum levels of placenta growth factor as an antecedent of clinical preeclampsia. Am J Obstet Gynecol (2001) 1.42
The role of uterine artery Doppler in predicting adverse pregnancy outcome. Best Pract Res Clin Obstet Gynaecol (2004) 1.34
Placental angiogenic growth factors and uterine artery Doppler findings for characterization of different subsets in preeclampsia and in isolated intrauterine growth restriction. Am J Obstet Gynecol (2006) 1.32
Plasma placenta growth factor levels in midtrimester pregnancies. Obstet Gynecol (2001) 1.31
Regulated expression on human macrophages of endoglin, an Arg-Gly-Asp-containing surface antigen. Eur J Immunol (1992) 1.31
Vascular endothelial growth factor, placenta growth factor and their receptors in isolated human trophoblast. Placenta (1997) 1.29
Identification of distinct epitopes of endoglin, an RGD-containing glycoprotein of endothelial cells, leukemic cells, and syncytiotrophoblasts. Int Immunol (1992) 1.28
Doppler ultrasound of the uterine arteries: the importance of bilateral notching in the prediction of pre-eclampsia, placental abruption or delivery of a small-for-gestational-age baby. Ultrasound Obstet Gynecol (1996) 1.25
Soluble VEGFR-1 secreted by endothelial cells and monocytes is present in human serum and plasma from healthy donors. Angiogenesis (2001) 1.25
One-stage screening for pregnancy complications by color Doppler assessment of the uterine arteries at 23 weeks' gestation. Obstet Gynecol (2000) 1.24
Molecular characterization and in situ localization of murine endoglin reveal that it is a transforming growth factor-beta binding protein of endothelial and stromal cells. Endocrinology (1994) 1.21
Doppler ultrasound screening as part of routine antenatal scanning: prediction of pre-eclampsia and intrauterine growth retardation. Br J Obstet Gynaecol (1993) 1.18
Evaluation of placenta growth factor and soluble Fms-like tyrosine kinase 1 receptor levels in mild and severe preeclampsia. Am J Obstet Gynecol (2006) 1.16
Circulating angiogenic factors and placental abruption. Obstet Gynecol (2006) 1.15
Fetoplacental angiogenesis during gestation is biphasic, longitudinal and occurs by proliferation and remodelling of vascular endothelial cells. Placenta (2002) 1.11
Cell type-specific expression of neuropilins in an MCA-occlusion model in mice suggests a potential role in post-ischemic brain remodeling. J Neuropathol Exp Neurol (2002) 1.09
A role of the anti-angiogenic factor sVEGFR-1 in the 'mirror syndrome' (Ballantyne's syndrome). J Matern Fetal Neonatal Med (2006) 1.08
Prospective analysis of placenta growth factor (PlGF) concentrations in the plasma of women with normal pregnancy and pregnancies complicated by preeclampsia. Hypertens Pregnancy (2004) 1.06
Hemochorial placentation in the primate: expression of vascular endothelial growth factor, angiopoietins, and their receptors throughout pregnancy. Biol Reprod (2002) 1.06
Second- and third-trimester serum levels of placental proteins in preeclampsia and small-for-gestational age pregnancies. Acta Obstet Gynecol Scand (2004) 1.04
Screening test for preeclampsia through assessment of uteroplacental blood flow and biochemical markers of oxidative stress and endothelial dysfunction. Am J Obstet Gynecol (2005) 1.04
Soluble VEGF receptor Flt1: the elusive preeclampsia factor discovered? J Clin Invest (2003) 1.04
Differential expression of endoglin on fetal and adult hematopoietic cells in human bone marrow. J Immunol (1995) 1.00
Doppler velocimetry studies of the uterine artery in the early prediction of pre-eclampsia and intra-uterine growth retardation. Eur J Obstet Gynecol Reprod Biol (1991) 0.98
Elevated sFlt1 level and preeclampsia with parvovirus-induced hydrops. N Engl J Med (2006) 0.98
Endoglin is expressed on a subpopulation of immature erythroid cells of normal human bone marrow. Leukemia (1991) 0.97
Does endothelial cell activation occur with intrauterine growth restriction? BJOG (2002) 0.96
Unexplained fetal death: another anti-angiogenic state. J Matern Fetal Neonatal Med (2007) 0.94
Differential levels of soluble endoglin (CD105) in myeloid malignancies. J Cell Physiol (2003) 0.91
Endoglin: a 180-kD endothelial cell and macrophage restricted differentiation molecule. Clin Exp Immunol (1992) 0.90
Role of placenta growth factor in cardiovascular health. Trends Cardiovasc Med (2002) 0.89
Is oxidative stress involved in the aetiology of pre-eclampsia? Acta Paediatr Suppl (2001) 0.89
Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med (2004) 14.00
Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest (2003) 13.72
Vitamin D-binding protein and vitamin D status of black Americans and white Americans. N Engl J Med (2013) 9.87
Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med (2006) 7.06
Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med (2011) 6.35
Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med (2006) 6.21
A novel signaling pathway impact analysis. Bioinformatics (2008) 5.06
Excess circulating angiopoietin-2 may contribute to pulmonary vascular leak in sepsis in humans. PLoS Med (2006) 3.72
Biological variation in HbA1c predicts risk of retinopathy and nephropathy in type 1 diabetes. Diabetes Care (2004) 3.59
The role of inflammation and infection in preterm birth. Semin Reprod Med (2007) 3.57
Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia. Circulation (2011) 3.33
The way forward. Lancet (2007) 3.28
Microbial prevalence, diversity and abundance in amniotic fluid during preterm labor: a molecular and culture-based investigation. PLoS One (2008) 3.01
Distinct subsets of microRNAs are expressed differentially in the human placentas of patients with preeclampsia. Am J Obstet Gynecol (2007) 2.78
Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension (2007) 2.77
Urinary placental growth factor and risk of preeclampsia. JAMA (2005) 2.76
Vascular endothelial growth factor is an important determinant of sepsis morbidity and mortality. J Exp Med (2006) 2.75
Bioavailable vitamin D is more tightly linked to mineral metabolism than total vitamin D in incident hemodialysis patients. Kidney Int (2012) 2.74
Vascular endothelial growth factor-A and aldosterone: relevance to normal pregnancy and preeclampsia. Hypertension (2013) 2.70
Pathogenesis of preeclampsia. Annu Rev Pathol (2010) 2.66
Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia. Hypertension (2007) 2.62
Inflammation in preterm and term labour and delivery. Semin Fetal Neonatal Med (2006) 2.59
Failure of physiologic transformation of the spiral arteries in patients with preterm labor and intact membranes. Am J Obstet Gynecol (2003) 2.55
Vitamin D-binding protein modifies the vitamin D-bone mineral density relationship. J Bone Miner Res (2011) 2.55
Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease. Circulation (2011) 2.55
High and low hemoglobin glycation phenotypes in type 1 diabetes: a challenge for interpretation of glycemic control. J Diabetes Complications (2002) 2.42
Intrauterine infection and prematurity. Ment Retard Dev Disabil Res Rev (2002) 2.42
The fetal inflammatory response syndrome. Clin Obstet Gynecol (2007) 2.36
Angiopoietin-2 may contribute to multiple organ dysfunction and death in sepsis*. Crit Care Med (2012) 2.32
Vitamin D deficiency and cardiovascular events in patients with coronary heart disease: data from the Heart and Soul Study. Am J Epidemiol (2014) 2.30
Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature (2012) 2.27
Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proc Natl Acad Sci U S A (2007) 2.25
The composition and stability of the vaginal microbiota of normal pregnant women is different from that of non-pregnant women. Microbiome (2014) 2.24
Clinical characterization and outcomes of preeclampsia with normal angiogenic profile. Hypertens Pregnancy (2013) 2.22
Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia. Hypertension (2005) 2.22
Listeriosis in human pregnancy: a systematic review. J Perinat Med (2011) 2.20
Early outcomes among those initiating chronic dialysis in the United States. Clin J Am Soc Nephrol (2011) 2.17
First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metab (2004) 2.11
The role of cervical cerclage in obstetric practice: can the patient who could benefit from this procedure be identified? Am J Obstet Gynecol (2006) 2.11
Preeclampsia: the role of angiogenic factors in its pathogenesis. Physiology (Bethesda) (2009) 2.10
Angiopoietin 2 is a partial agonist/antagonist of Tie2 signaling in the endothelium. Mol Cell Biol (2009) 2.09
Preeclampsia and angiogenic imbalance. Annu Rev Med (2008) 2.05
Circulating levels of the antiangiogenic marker sFLT-1 are increased in first versus second pregnancies. Am J Obstet Gynecol (2005) 2.03
Endothelial dysfunction: a link among preeclampsia, recurrent pregnancy loss, and future cardiovascular events? Hypertension (2006) 2.02
Inflammation in pregnancy: its roles in reproductive physiology, obstetrical complications, and fetal injury. Nutr Rev (2007) 2.01
Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia. J Matern Fetal Neonatal Med (2005) 1.99
[A national birth weight distribution curve according to gestational age in Chile from 1993 to 2000]. Rev Med Chil (2004) 1.94
Abortion, changed paternity, and risk of preeclampsia in nulliparous women. Am J Epidemiol (2003) 1.91
Molecular mechanisms of preeclampsia. Microvasc Res (2007) 1.90
Evolution of the mammalian placenta revealed by phylogenetic analysis. Proc Natl Acad Sci U S A (2006) 1.89
PGC-1α promotes recovery after acute kidney injury during systemic inflammation in mice. J Clin Invest (2011) 1.88
Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation (2012) 1.88
Transcriptionally active syncytial aggregates in the maternal circulation may contribute to circulating soluble fms-like tyrosine kinase 1 in preeclampsia. Hypertension (2012) 1.86
A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia. J Matern Fetal Neonatal Med (2009) 1.84
A sonographic short cervix as the only clinical manifestation of intra-amniotic infection. J Perinat Med (2006) 1.82
Recombinant vascular endothelial growth factor 121 infusion lowers blood pressure and improves renal function in rats with placentalischemia-induced hypertension. Hypertension (2009) 1.82
Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award. Am J Obstet Gynecol (2004) 1.81
Diagnostic utility of soluble fms-like tyrosine kinase 1 and soluble endoglin in hypertensive diseases of pregnancy. Am J Obstet Gynecol (2007) 1.80
The neuropathology of fatal cerebral malaria in malawian children. Am J Pathol (2011) 1.79
Misclassification of maternal smoking status and its effects on an epidemiologic study of pregnancy outcomes. Nicotine Tob Res (2007) 1.78
Soluble Fms-like tyrosine kinase 1 and endothelial dysfunction in the pathogenesis of preeclampsia. Pediatr Res (2005) 1.78
Infection and prematurity and the role of preventive strategies. Semin Neonatol (2002) 1.78
Metabolomics in premature labor: a novel approach to identify patients at risk for preterm delivery. J Matern Fetal Neonatal Med (2010) 1.77
Identification of fetal and maternal single nucleotide polymorphisms in candidate genes that predispose to spontaneous preterm labor with intact membranes. Am J Obstet Gynecol (2010) 1.75
Prevalence and diversity of microbes in the amniotic fluid, the fetal inflammatory response, and pregnancy outcome in women with preterm pre-labor rupture of membranes. Am J Reprod Immunol (2010) 1.74